Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
China
Peking Union Medical College Hospital, Beijing, Beijing Municipality Hunan Provincial Tumor Hospital, Hunan, Changsha The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing Municipality Fujian provincial cancer hospital, Fuzhou, Fujian Second Affiliated Hospital of Hainan Medical University, Haikou, Hainan Harbin medical university cancer hospital, Heilongjiang, Harbin Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality West China Hospital, Sichuan University, Chengdu, Sichuan The First Affiliated Hospital of Zhengzhou University, Henan, Zhengzhou